Truist Financial Maintains a Buy Rating on Autolus Therapeutics (AUTL)

Autolus Therapeutics plc (NASDAQ:AUTL) is one of the best strong buy penny stocks to buy now. On June 17, Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Autolus Therapeutics plc (NASDAQ:AUTL) without a price target.

A laboratory technician carefully studying a microscope with a biopharmaceutical product inside.

In other news, Autolus Therapeutics plc (NASDAQ:AUTL) announced on July 21 that the European Commission (EC) granted marketing authorization for AUCATZYL for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Management reported that the EC approval was based on the results of the FELIX study, which is “an open-label, multi-centre, single arm study in adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia”.

Autolus Therapeutics (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company based in the United Kingdom. It develops programmed T cell therapies for treating autoimmune diseases and cancer and focuses on chimeric antigen receptor (CAR) T cell therapy.

The company engineers controlled, targeted, and highly active T cell therapy product candidates designed to recognize target cells, break their defense mechanisms down, and eliminate them. It is doing so using a portfolio of proprietary and modular T-cell programming technologies.

While we acknowledge the potential of AUTL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AUTL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.